Neumora Therapeutics Statistics
Total Valuation
NMRA has a market cap or net worth of $112.01 million. The enterprise value is -$193.71 million.
| Market Cap | 112.01M |
| Enterprise Value | -193.71M |
Important Dates
The last earnings date was Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NMRA has 161.75 million shares outstanding. The number of shares has increased by 64.89% in one year.
| Current Share Class | 161.75M |
| Shares Outstanding | 161.75M |
| Shares Change (YoY) | +64.89% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 25.40% |
| Owned by Institutions (%) | 56.55% |
| Float | 53.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.39 |
| P/TBV Ratio | 0.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -47.77% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.35M |
| Employee Count | 110 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NMRA has paid $283,000 in taxes.
| Income Tax | 283,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.46% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -92.46% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 7.25 |
| Relative Strength Index (RSI) | 36.89 |
| Average Volume (20 Days) | 920,839 |
Short Selling Information
The latest short interest is 12.78 million, so 7.90% of the outstanding shares have been sold short.
| Short Interest | 12.78M |
| Short Previous Month | 13.30M |
| Short % of Shares Out | 7.90% |
| Short % of Float | 23.96% |
| Short Ratio (days to cover) | 10.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -274.33M |
| Pretax Income | -273.79M |
| Net Income | -258.06M |
| EBITDA | -273.70M |
| EBIT | -274.33M |
| Earnings Per Share (EPS) | -$1.61 |
Balance Sheet
The company has $307.58 million in cash and $1.85 million in debt, giving a net cash position of $305.73 million or $1.89 per share.
| Cash & Cash Equivalents | 307.58M |
| Total Debt | 1.85M |
| Net Cash | 305.73M |
| Net Cash Per Share | $1.89 |
| Equity (Book Value) | 287.06M |
| Book Value Per Share | 1.78 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NMRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -64.89% |
| Shareholder Yield | -64.89% |
| Earnings Yield | -230.39% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NMRA is $9.29, which is 1,241.52% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.29 |
| Price Target Difference | 1,241.52% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -20.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |